These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1021 related items for PubMed ID: 9432985

  • 21. CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences.
    Romero P, Dutoit V, Rubio-Godoy V, Liénard D, Speiser D, Guillaume P, Servis K, Rimoldi D, Cerottini JC, Valmori D.
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):766s-772s. PubMed ID: 11300471
    [Abstract] [Full Text] [Related]

  • 22. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.
    Jäger E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jäger D, Arand M, Ritter G, Old LJ, Knuth A.
    Int J Cancer; 1999 Oct 22; 84(5):506-10. PubMed ID: 10502728
    [Abstract] [Full Text] [Related]

  • 23. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
    Robson NC, McAlpine T, Knights AJ, Schnurr M, Shin A, Chen W, Maraskovsky E, Cebon J.
    Blood; 2010 Jul 15; 116(2):218-25. PubMed ID: 20430956
    [Abstract] [Full Text] [Related]

  • 24. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
    Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjölander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A.
    Clin Cancer Res; 2004 Apr 15; 10(8):2879-90. PubMed ID: 15102697
    [Abstract] [Full Text] [Related]

  • 25. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
    Krönig H, Hofer K, Conrad H, Guilaume P, Müller J, Schiemann M, Lennerz V, Cosma A, Peschel C, Busch DH, Romero P, Bernhard H.
    Int J Cancer; 2009 Aug 01; 125(3):649-55. PubMed ID: 19444908
    [Abstract] [Full Text] [Related]

  • 26. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
    Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ.
    J Exp Med; 1998 Apr 20; 187(8):1349-54. PubMed ID: 9547346
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM.
    Cancer Res; 2002 Jan 01; 62(1):213-8. PubMed ID: 11782380
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
    Bernhard H, Jäger E, Maeurer MJ, Meyer zum Büschenfelde KH, Knuth A.
    Tissue Antigens; 1996 Jul 01; 48(1):22-31. PubMed ID: 8864171
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
    Bioley G, Guillaume P, Luescher I, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Valmori D, Ayyoub M.
    Clin Cancer Res; 2009 Jan 01; 15(1):299-306. PubMed ID: 19118058
    [Abstract] [Full Text] [Related]

  • 35. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM.
    Cancer Res; 2000 Sep 01; 60(17):4946-52. PubMed ID: 10987311
    [Abstract] [Full Text] [Related]

  • 36. In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.
    Schmidt J, Guillaume P, Dojcinovic D, Karbach J, Coukos G, Luescher I.
    J Biol Chem; 2017 Jul 14; 292(28):11840-11849. PubMed ID: 28536262
    [Abstract] [Full Text] [Related]

  • 37. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
    Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, Ikuta Y, Yokomine K, Imai K, Inoue M, Harada K, Mori T, Tsunoda T, Nakatsuru S, Daigo Y, Nomori H, Nakamura Y, Baba H, Nishimura Y.
    Int J Cancer; 2008 Dec 01; 123(11):2616-25. PubMed ID: 18770861
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
    Karbach J, Pauligk C, Bender A, Gnjatic S, Franzmann K, Wahle C, Jäger D, Knuth A, Old LJ, Jäger E.
    Int J Cancer; 2006 Feb 01; 118(3):668-74. PubMed ID: 16152624
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.